News the two companies were beginning tests on their drugs as a combination therapy for prostate cancer drove their stock values up more than 5%. The multidose, dose-escalation trial is on Medarex's antibody treatment MDX-010, thought to help shrink some tumors, combined with Cell Genesys' investigative cancer vaccine GVAX, and involves up to 45 patients with advanced prostate tumors. Researchers are looking for safety factors and a maximum-tolerated dose level.

Full Story:
Forbes, MarketWatch

Related Summaries